본문으로 건너뛰기
← 뒤로

Lymph Node Harvest and Survival Among Patients With Locally Advanced Appendiceal Adenocarcinoma.

1/5 보강
The Journal of surgical research 2026 Vol.321() p. 308-316
Retraction 확인
출처

PICO 자동 추출 (휴리스틱, conf 2/4)

유사 논문
P · Population 대상 환자/모집단
9743 patients, 15.
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
[CONCLUSIONS] LN harvest is associated with improved survival in node-negative, locally advanced appendiceal adenocarcinoma. While it did not clearly delineate patients benefitting from adjuvant chemotherapy, differential effects by LN harvest may exist in patients with inadequate LN harvest and lymphovascular invasion.

Zhang GQ, Farber ON, Tran A, Melnitchouk N, Irani JL, Bleday R, Goldberg JE

📝 환자 설명용 한 줄

[INTRODUCTION] Despite a distinct biology, the management of locally advanced appendiceal cancer, including recommended lymph node (LN) harvest and indications for adjuvant chemotherapy, is largely ba

🔬 핵심 임상 통계 (초록에서 자동 추출 — 원문 검증 권장)
  • 95% CI 0.41-0.58

이 논문을 인용하기

BibTeX ↓ RIS ↓
APA Zhang GQ, Farber ON, et al. (2026). Lymph Node Harvest and Survival Among Patients With Locally Advanced Appendiceal Adenocarcinoma.. The Journal of surgical research, 321, 308-316. https://doi.org/10.1016/j.jss.2026.03.021
MLA Zhang GQ, et al.. "Lymph Node Harvest and Survival Among Patients With Locally Advanced Appendiceal Adenocarcinoma.." The Journal of surgical research, vol. 321, 2026, pp. 308-316.
PMID 41921468

Abstract

[INTRODUCTION] Despite a distinct biology, the management of locally advanced appendiceal cancer, including recommended lymph node (LN) harvest and indications for adjuvant chemotherapy, is largely based on colon cancer treatment algorithms. We evaluated associations between LN harvest and survival in appendiceal cancer, and whether LN harvest informed which patients with node-negative disease benefited from adjuvant chemotherapy.

[METHODS] Patients with pathologic stage II-III appendiceal adenocarcinoma undergoing major resection (2004-2022) were identified from the National Cancer Database, and stratified by nodal status and harvest: pN0 with 0-11, 12-23, or ≥24 LNs, and pN1+. Multivariable Cox proportional hazards models were used to estimate overall survival and evaluate adjuvant chemotherapy benefit across LN harvest groups.

[RESULTS] Among 9743 patients, 15.4% were pN0 with 0-11 LNs, 36.1% with 12-23 LNs, 15.5% with ≥24 LNs, and 32.9% were pN1+. Those who were pN0 with 12-23 or ≥24 LNs harvested had lower risk of mortality than those with 0-11 LNs (adjusted hazard ratio [aHR] 0.73, 95% confidence interval [CI] 0.65-0.83; aHR 0.49, 95% CI 0.41-0.58; respectively). Node-positive disease was associated with the highest mortality risk (aHR 2.01, 95% CI 1.80-2.26). Adjuvant chemotherapy was not associated with improved survival among patients with node-negative disease. In the subgroup of patients whose tumors exhibited lymphovascular invasion, when <12 LNs were harvested, chemotherapy was associated with improved survival. This was not observed among patients with 12-23 or ≥24 LNs harvested, though the interaction was not statistically significant.

[CONCLUSIONS] LN harvest is associated with improved survival in node-negative, locally advanced appendiceal adenocarcinoma. While it did not clearly delineate patients benefitting from adjuvant chemotherapy, differential effects by LN harvest may exist in patients with inadequate LN harvest and lymphovascular invasion.

같은 제1저자의 인용 많은 논문 (3)